Bextra (valdecoxib) is a medication used in the management of symptoms related to pain and inflammation. The medication's role involves addressing symptoms such as stiffness, swelling, and discomfort.

The approved therapeutic areas for Bextra included the symptomatic management of osteoarthritis and rheumatoid arthritis, and also addressing primary dysmenorrhoea (menstrual discomfort). The medication aimed to help mitigate discomfort linked to these conditions.

The medication's aim was to assist with discomfort and inflammation linked to these joint and muscular conditions.

Quick Fact: Relief for Joint Pain

While Bextra was authorized for these uses, the drug was ultimately withdrawn from the market in the U.S., Canada, and Europe due to noted safety considerations. The medication was used to help mitigate the symptoms of these conditions, which may support comfort and movement.

Official Eligibility Rules for Bextra (Valdecoxib)

The official label for Bextra strictly defines which patient populations can use the medicine and which are absolutely excluded, based on authoritative regulatory documentation. The medication is authorized for use only in adults 18 years of age and older.

Populations Who Must Not Use Bextra (Contraindications)

Bextra is contraindicated and must not be used by patients with:

• A known allergy or hypersensitivity to valdecoxib, sulfonamides, or other NSAIDs (e.g., aspirin-induced asthma).
• Active gastrointestinal (GI) bleeding or peptic ulceration.
• Established ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease.
• Congestive heart failure (NYHA Class II–IV) or for treating pain after Coronary Artery Bypass Graft (CABG) surgery.
• Severe hepatic dysfunction (e.g., Child-Pugh score ge 10) or severe renal impairment.
• During the third trimester of pregnancy or while breastfeeding.

Restricted and Non-Recommended Use

Use is not recommended in children and adolescents under 18 due to insufficient data. Older adults (over 65) and patients with moderate hepatic impairment (Child-Pugh score 7–9) require conditional use, typically starting at the lowest dose.

Bextra Interactions with other medicines and products

Official regulatory documents detail specific pharmacokinetic (PK) and pharmacodynamic (PD) interaction patterns for Valdecoxib (Bextra). The drug's metabolism is managed by CYP2C9 and CYP3A4 enzymes, and Valdecoxib acts as an inhibitor of CYP2C9 and CYP2C19.

Documented Pharmacokinetic Interactions

Co-administration with CYP inhibitors, such as Fluconazole and Ketoconazole, is officially documented to increase the total plasma exposure of Valdecoxib. Conversely, co-administration with a CYP inducer like Phenytoin decreases Valdecoxib exposure. Since Valdecoxib inhibits specific CYPs, it causes increased exposure of co-administered substrates, including Warfarin, Glyburide, Diazepam, and certain Oral Contraceptives.

Pharmacodynamic and Setting Restrictions

Co-administration with Warfarin leads to a documented increase in anticoagulant effect (INR), which is a pharmacodynamic reinforcement. Valdecoxib may also diminish the antihypertensive effect of ACE inhibitors and ARBs, and reduce the natriuretic effect of Diuretics. Use of Valdecoxib is formally contraindicated for treating pain immediately following Coronary Artery Bypass Graft (CABG) surgery and in patients with known hypersensitivity to Aspirin or other NSAIDs.

Food and Substance Interactions

Administration with a high-fat meal has been found to delay the time to peak concentration (Tmax), although the overall extent of absorption (AUC) is not significantly altered. Antacids (aluminum/magnesium hydroxide) do not significantly affect Valdecoxib absorption. In specific populations, such as those with moderate hepatic impairment, Valdecoxib exposure is significantly increased.

Selective Inhibition of the COX-2 Enzyme

Bextra (valdecoxib) functions by selectively targeting and inhibiting the Cyclooxygenase-2 ( COX-2) enzyme, which is primarily responsible for producing pro-inflammatory chemical messengers. This focused interaction blocks a key early molecular step in the cascade that links tissue stress to subsequent biological responses, resulting in a modulation of physiological responses.

Modulating Prostaglandin Biosynthesis

This mechanism operates within the prostaglandin biosynthesis pathway, where COX-2 inhibition leads to a sharp reduction in the synthesis of prostaglandins ( PGs), such as PGE2, at sites of COX-2 induction. By limiting the availability of these mediators, the drug influences the signaling dynamics that trigger localized edema and nociceptor sensitization.

Modulation of Peripheral Nociceptive Signaling

The drug's activity is concentrated on peripheral tissues, where its action limits the chemical input that activates nociceptors and transmits signals. This focused peripheral mechanism contributes to the stabilization of localized physiological responses by reducing inflammation-driven chemical hypersensitivity. The primary observable physiological consequence is the reduction of localized nociceptor sensitization.

How Bextra (Valdecoxib) is Used

Bextra is used based on established guidelines, with dosing determined by the condition being managed and the patient's individual characteristics. The medication is formulated as film-coated tablets and is administered exclusively via the oral route.

---

Dosing Schedules and Frequency

Dosing is typically structured into regimens for chronic management versus short-term relief:

• For Osteoarthritis and Rheumatoid Arthritis: The usual starting dose is 10 mg taken once daily. The dose may be increased to a maximum of 20 mg once daily if additional relief for chronic symptoms is required.
• For Primary Dysmenorrhoea: This condition is managed with short-term, intermittent use. The recommended dose is 40 mg once daily as needed. An additional 40 mg may be taken on the first day of treatment for an initial maximum of 80 mg, with subsequent daily doses not exceeding 40 mg. Another utilized regimen for this condition involves a dose of 20 mg taken twice daily.

---

Administration Conditions and Adjustments

Valdecoxib tablets may be taken with or without food; however, consuming it with food can delay the time to peak concentration.

Special Population Guidance:

Treatment is initiated with caution and at the lowest recommended dose (10 mg daily) for older adults (especially those weighing less than 50 kg) and for patients with moderate hepatic impairment. For the latter group, the dose for acute pain should not exceed 20 mg daily. If a dose is missed, it is typically taken as soon as remembered, unless it is near the time for the next scheduled dose, in which case the missed dose is skipped. A double dose is not taken to compensate for a missed one.

Research evidence / Overview of Studies for Bextra (Valdecoxib)

---

Evidence for Symptomatic Management of Osteoarthritis (OA) and Rheumatoid Arthritis (RA)

Research for chronic joint conditions focused on Randomized Controlled Trials (RCTs) in which valdecoxib was studied for adult patients diagnosed with osteoarthritis (OA) and rheumatoid arthritis (RA). These studies were used in research exploring how symptoms change over time. Researchers examined outcomes related to physical discomfort, such as pain intensity, and daily functioning or activity level. Findings describe patterns observed in the studies where patients receiving valdecoxib reported differences in perceived discomfort when compared to those on placebo. Studies explored comparative research against other non-steroidal anti-inflammatory drugs (NSAIDs), where reported outcomes showed patterns related to those observed across active treatment groups over the duration of the trials.

Evidence for Acute Pain Relief and Primary Dysmenorrhoea

Valdecoxib was evaluated in studies focusing on episodic or acute changes in pain. This research primarily involved short-term, acute pain RCTs conducted in settings such as post-operative dental and general surgery pain, and conditions characterized by fluctuating or episodic manifestations like primary dysmenorrhoea (menstrual discomfort). Studies explored outcomes describing episodic or acute changes, primarily measuring the intensity of pain relief and the use of rescue medication. Data show patterns related to differences in the reported use of rescue medication in groups receiving valdecoxib compared to those receiving placebo in the acute post-treatment phase.

What is Still Uncertain in the Research Record

The research record points to several key limitations and areas of uncertainty. Follow-up durations were limited for chronic conditions like OA and RA, meaning that long-term effects are not fully established. Scientific certainty remains low regarding long-term effects. Furthermore, research does not determine whether an individual will respond similarly to group averages, as results apply only to the populations studied. Data for certain groups (e.g., children, pregnant populations) remain insufficient, and research related to specific high-risk surgical settings was associated with specific documented limitations.

Key Studies & References

1. ANNEX SCIENTIFIC CONCLUSIONS AND GROUNDS FOR THE SUSPENSION OF THE MARKETING AUTHORISATION - Bextra, INN-valdecoxib - European Union (EMA)

Common questions about Bextra (FAQ)

---

Q: How quickly does Bextra start working after taking it?

Official pharmacological data indicates that the active ingredient, valdecoxib, generally reached its highest concentration in the blood within three hours in clinical studies. Official prescribing information also notes that consuming the tablet with food may delay the time it takes to reach this peak concentration.

---

Q: How long do the effects of Bextra usually last?

The duration of the drug's action is related to its elimination half-life, which is the time it takes for half of the drug to be cleared from the body. Official pharmacological data indicates the elimination half-life of valdecoxib is approximately 8 to 11 hours.

---

Q: What is still uncertain in the research record about Bextra?

Official regulatory documents indicate that scientific certainty remains low regarding the long-term effects of Bextra, primarily because follow-up periods in studies for chronic conditions were limited. Furthermore, official documents note that results apply only to the populations studied and do not predict an individual's specific response.

---

Q: Does taking Bextra affect blood pressure?

Official information documents state that valdecoxib may lessen the effects of certain blood pressure medications, specifically ACE inhibitors and ARBs. The official label indicated an increased rate of elevated blood pressure was noted with dosages above 20 mg per day.

---

Q: Is Bextra an option for people with stomach ulcers?

Bextra is contraindicated (excluded from use) for patients with active gastrointestinal bleeding or a peptic ulceration. Regulatory warnings also emphasize the potential for serious gastrointestinal side effects, including ulceration and perforation of the stomach or intestines.

---

Q: Why was Bextra taken off the market?

Bextra was voluntarily withdrawn from the global market in 2005. The decision was prompted by regulatory concerns, which cited insufficient long-term data on cardiovascular safety, an increased risk of serious cardiovascular events in certain post-surgical patients, and reports of severe, sometimes life-threatening, skin reactions (SCARs).

---

Q: Is Bextra the same type of pain reliever as ibuprofen or naproxen?

Bextra (valdecoxib), ibuprofen, and naproxen all belong to the broader class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Bextra is specifically a selective Cyclooxygenase-2 (COX-2) inhibitor (a type of Coxib), while ibuprofen and naproxen are traditional, non-selective NSAIDs.

---

Q: Is Bextra more selective than older pain medications?

Yes, Bextra is classified as a Cyclooxygenase-2 Selective Inhibitor (Coxib). This is a designation that reflects its mechanism of action, which is designed to selectively target the enzyme primarily involved in generating pain and inflammation signals, differentiating it from traditional non-selective NSAIDs.

---

Q: Does Bextra interact with blood thinners?

Official regulatory documents specifically address co-administration with the blood thinner Warfarin. These documents note that Bextra may lead to a documented increase in Warfarin's anticoagulant effect, which documents an increased risk of bleeding.

---

Q: Is Bextra safe for use in older adults?

Official guidance states that Bextra is authorized for adults but recommends initiating treatment with caution and at the lowest dose for older adults, particularly those who weigh less than 50 kg. This caution is related to the potential for higher drug exposure noted in this population.

---

Q: Can Bextra be used by people with a history of heart disease?

Bextra is strictly contraindicated for patients with several serious heart conditions, including established ischaemic heart disease, peripheral arterial disease, or certain stages of congestive heart failure. Its use is also contraindicated for pain treatment following Coronary Artery Bypass Graft (CABG) surgery.

---

Q: What is the difference between Bextra and Celebrex (celecoxib)?

Both Bextra (valdecoxib) and Celebrex (celecoxib) are in the same therapeutic class of COX-2 selective inhibitors. Regulatory assessments observed that valdecoxib was associated with a higher potential for causing Severe Cutaneous Adverse Reactions (SCARs) than celecoxib.

---

Q: Are there any ongoing studies or new data about Bextra?

Since Bextra is no longer commercially available, new large-scale clinical trials are not typically conducted. However, research databases like the U.S. National Institutes of Health (NIH) registry may list small, exploratory, or academic studies that have examined valdecoxib for specific research purposes.

---

Q: Is Bextra still available in any country?

No. Bextra (valdecoxib) was voluntarily withdrawn from the market by the manufacturer globally in 2005 following regulatory agency requests. It is no longer commercially available in the United States, Europe, Canada, or Australia.

---

Q: If Bextra isn't available, what alternative medicine class is similar?

The medication class most pharmacologically similar to Bextra is the group of other selective Cyclooxygenase-2 (COX-2) inhibitors (Coxibs). These drugs were developed for the same therapeutic purpose—managing pain and inflammation—and remain available on the market.

---

Q: Is Bextra known to cause drowsiness or affect driving?

The official side-effect profile lists headache and dizziness as common reactions. Due to the potential for symptoms like dizziness or drowsiness, official warnings advise caution when driving or operating machinery.

---

Q: Can Bextra be taken with alcohol?

Official regulatory warnings for NSAIDs indicate that using the medication concurrently with alcohol may increase the risk of gastrointestinal irritation and bleeding.

---

Q: Does Bextra interfere with birth control pills?

Official regulatory documents indicate that Bextra inhibits specific enzymes that can increase the plasma exposure of co-administered substrates, including certain Oral Contraceptives. This interaction may alter the levels of the birth control medication in the body.

---

Q: Is the long-term safety of Bextra known?

According to the research record, follow-up durations for chronic conditions were limited, meaning that long-term effects are not fully established. Scientific certainty regarding the long-term safety profile remains low.

---

Q: What is the elimination process of Bextra from the body?

Valdecoxib is primarily broken down in the liver via metabolic enzymes (CYP P450). Less than 5% of the dose is excreted unchanged, while approximately 70% of the dose is excreted in the urine as inactive metabolites.

---

Q: Is Bextra addictive or habit-forming?

Valdecoxib is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This class of medication is not associated with the dependence risks seen with opioid analgesics.

---

Q: Does Bextra affect fertility?

Regulatory documents for drugs in the NSAID class often include a warning that, like other drugs that inhibit prostaglandin synthesis, Bextra may impair fertility in females. This effect has been described as reversible upon discontinuation of the drug.

---

Q: What type of pain does Bextra manage best?

Bextra's overall therapeutic purpose is to provide symptomatic relief through its pain-relieving, anti-inflammatory, and fever-reducing properties. It was approved for managing chronic pain associated with osteoarthritis and rheumatoid arthritis, as well as acute, episodic pain, such as primary dysmenorrhoea.

---

Q: Were there concerns about clinical trial integrity for Bextra?

Public regulatory documents indicate that the manufacturer of Bextra was subject to legal action regarding the promotion and marketing of the drug. The regulatory action related to the promotion of uses and dosages that were not officially approved as safe and effective.

---

Q: Is Bextra related to Vioxx (rofecoxib)?

Yes, Bextra (valdecoxib) and Vioxx (rofecoxib) were both members of the selective Cyclooxygenase-2 (COX-2) inhibitor drug class. Both drugs were subjected to similar regulatory reviews regarding the potential risks within their cardiovascular safety profiles.

---

Q: What is the half-life of Bextra?

The official elimination half-life is approximately 8 to 11 hours, which is the time it takes for the amount of drug in the body to be reduced by half. Pharmacological data indicates this can increase slightly in older adults.

---

Q: Did Bextra receive a Boxed Warning from the FDA?

Yes. Prior to its withdrawal from the market, the FDA required a Boxed Warning to be added to Bextra's labeling. This is the strongest warning the FDA mandates and it highlighted the risks of serious cardiovascular thrombotic events and severe, life-threatening skin reactions.

Bextra (valdecoxib) tablets, prior to their market withdrawal, were subject to specific regulatory storage and disposal mandates.

Storage Conditions

Official labeling required Bextra to be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The medication must be kept in a closed container, in a dry place, and away from heat and moisture to ensure product stability.

Protection and Handling

As a safety mandate, Bextra must be stored out of the reach of children. Excursions outside the standard range, up to 30 C, were permitted only for short periods.

Disposal Instructions

Disposal of unused or expired tablets should follow official governmental guidance. This typically involves utilizing a drug take-back program or, if unavailable, mixing the medication with an undesirable household substance (like coffee grounds or dirt) and placing it into a sealed container before discarding it in the household trash.